CTXR Citius Pharmaceuticals Inc Forecast, Technical & Fundamental Analysis
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products... Show more
CTXR is expected to report earnings to fall 103.27% to 3 cents per share on August 17
Q2'26
Est.
$0.03
Q1'26
Missed
by $0.75
Q3'25
Missed
by $0.51
Q2'25
Missed
by $0.85
Q1'25
Missed
by $1.31
The last earnings report on May 15 showed earnings per share of -94 cents, missing the estimate of -20 cents. With 65.19K shares outstanding, the current market capitalization sits at 15.96M.
A.I.dvisor tells us that CTXR and HYPD have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CTXR and HYPD's prices will move in lockstep.
CTXR in upward trend: price may ascend as a result of having broken its lower Bollinger Band on May 18, 2026
CTXR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 35 cases where CTXR's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Momentum Indicator moved above the 0 level on June 22, 2026. You may want to consider a long position or call options on CTXR as a result. In of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for CTXR just turned positive on June 22, 2026. Looking at past instances where CTXR's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CTXR advanced for three days, in of 216 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CTXR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for CTXR entered a downward trend on May 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.259) is normal, around the industry mean (20.966). P/E Ratio (0.000) is within average values for comparable stocks, (36.007). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). CTXR has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (1.867) is also within normal values, averaging (367.026).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. CTXR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CTXR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
